Last checked at | Director Dealings Summary - Week Ended April 10 | ||||||||||||
| Company | Name | Position | Number of Shares | Resulting Holding | *Note | GBP Value | ||||||
| BUYS | ||||||||||||
| Hutchison China MediTech | Simon To | Chairman | 58,000 | 127,000 | 800,000 | |||||||
| Strategic Minerals | John Peters | Chairman | 1 million | 1 million | First purchase. | 600,000 | ||||||
| Hutchison China MediTech | Edith Shih | Non-Executive Director | 12,000 | 60,000 | 166,000 | |||||||
| Hydrodec | Andrew Black | Non-Executive Director | 1,750,000 | 183.6 million | Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. | 121,000 | ||||||
| Dunedin Enterprise Investment Trust | Duncan Budge | Chairman | 20,000 | 35,900 | Week after making GBP5 million investment in Blackrock Programme Management. | 68,000 | ||||||
| Amerisur Resources | John Wardle | CEO | 248,000 | 17.6 million | Purchased by Tracarta in which Wardle has a beneficial interest. | 60,000 | ||||||
| Amerisur Resources | Douglas Ellenor | Non-Executive Director | 200,000 | 1.2 million | Same day as pretax profit fell during 2014 and revenue was offset by impairment charge. | 50,000 | ||||||
| Chime Communications | Mervyn Davies | Chairman | 17,936 | 67,785 | 50,000 | |||||||
| Synety | Graham Ward | Non-Executive Director | 28,075 | 234,870 | 2 days after share placing and open offer. | 25,000 | ||||||
| JPMorgan Brazil Investment Trust | Victor Bulmer-Thomas | Non-Executive Director | 43,750 | 159,850 | 24,000 | |||||||
| Hydrodec | Colin Moynihan | Chairman | 310,155 | 10.2 million | Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. | 20,000 | ||||||
| Xaar | Edmund Creutzmann | CTO | 4,846 | 4,846 | First purchase. | 20,000 | ||||||
| Dunedin Enterprise Investment Trust | Federico Marescott | Director | 6,000 | 10,000 | Week after making GBP5 million investment in Blackrock Programme Management. | 20,000 | ||||||
| Synectics | Peter Rae | Non-Executive Director | 14,000 | 232,302 | 18,000 | |||||||
| Michelmersh | Frank Hanna | Commercial Director | 21,985 | 1.3 million | 2 weeks after reinstating its dividend payout. | 15,000 | ||||||
| Hydrodec | Ian Smale | CEO | 200,000 | 1.1 million | Day after Hydrodec agreed to buy Eco-Oil International for GBP2.4 million. | 14,000 | ||||||
| Amerisur Resources | Nick Harrison | CFO | 50,000 | 5.7 million | Same day as pretax profit fell during 2014 and revenue was offset by impairment charge. | 12,000 | ||||||
| Standard Life | Elizabeth Noel Harwerth | Non-Executive Director | 1,893 | 10,074 | 8,900 | |||||||
| Concurrent Technologies | David Evans-Hughes | Engineering Director | 8,755 | 948,206 | 3,900 | |||||||
| SELLS | ||||||||||||
| Amec Foster Wheeler | Kent Masters | Non-Executive Director | 347,273 | 70,000 (in the form of ADRs) | Week after winning EDF Energy UK nuclear power station deal. | 3,800,000 | ||||||
| CVS Group | Simon Innes | CEO | 300,000 | 246,475 | Sold more than half his stake. | 1,700,000 | ||||||
| Domino Printing Sciences | Peter Byrom | Chairman | 11,932 | 338,000 | 111,000 | |||||||
| *Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director. | ||||||||||||
| Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam | ||||||||||||
| Copyright 2015 Alliance News Limited. All Rights Reserved. | ||||||||||||
3 May 2022 11:25
IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing
Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."
Read more